PandemicPreparedness

20 July: The CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Adult Work Group has reported that vaccination with a single dose of either the GSK or Pfizer vaccine demonstrated "moderate to high efficacy" in preventing Respiratory Syncytial Virus (RSV) associated lower respiratory tract disease in persons aged 60 years and older. Additionally, evidence suggests vaccination may prevent considerable RSV in this population.

Until further evidence is available clarifying any potential risks, the CDC recommends vaccination primarily for those at highest risk for severe RSV, as they are most likely to benefit from vaccination.

29 June: Authorities have recommended the use of new Respiratory Syncytial Virus (RSV) vaccines from GSK and Pfizer for persons aged 60 years and older. Eligible individuals may receive a single dose of the vaccine after consultation with their healthcare provider about whether RSV vaccination is right for them. Those at highest risk for severe disease from RSV include older adults, adults with chronic heart or lung disease or a weakened immune system, and adults living in nursing homes or long-term care facilities.

These new vaccines, the first licensed in the U.S. against RSV, are expected to become available this fall.